Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Beginner's Mind

Beginner's Mind artwork

#104: Revolutionizing Respiratory Antivirals: The Science behind G.ST Antivirals

Jan 22, 202335 minAudio
ShareXLinkedInFacebookWhatsAppEmail

On this episode of "Year in Review Recording," we speak with Guido Gualdoni, Co-Founder, and CEO of G.ST Antivirals, a clinical-stage biotech company revolutionizing how we treat viral infections of the respiratory tract. Guido shares the science behind G.ST Antivirals' innovative host cell-based strategy to develop broad-spectrum antivirals and how it completely eliminates viral reproduction without the risk of resistance development. He also delves into the public funding and startup ecosystem in Vienna, Austria, which has been instrumental in the company's success. He also talks about the future plans for G.ST Antivirals and the deep scientific tech valley in Central Europe. This episode is a must-listen for anyone interested in the latest advancements in biotech and the companies leading the way in treating viral infections. 💡 LINKS TO MORE CONTENT. If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe Podcast Episodes: https://pod.link/1493847125 Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2 Watch on Youtube Guido Gualdoni Christian Soschner ⏰ Timestamps: (00:00) Welcome to the Episode: Exploring the Public Funding and Eco-System in Vienna, Austria (02:35) Meet Guido Gualdoni, CEO of G.ST Antiviral (04:00) Discovering the StartUp Labs, Vienna Business Agency, AWS, FFG, Austrian Business Agency, LISA Vienna and their role in supporting startups (07:35) Exploring the Scientific Deep Tech Valley in Central Europe: Munich, Vienna, Zurich, Prague (10:15) G.ST Antiviral's 2022 Outlook (11:22) Uncovering the Innovative Technology Behind G.ST Antiviral (14:30) Guido's Biggest Takeaways from 2022 (16:15) Why Optimism Bias Can be a Challenge for Entrepreneurs (18:15) Comparing the Scientific and Entrepreneurial Mindsets (24:00) The Surprising Companies that Succeeded During Economic Downturns (25:00) Examining the Latest Trends in Antiinfectious Diseases (27:45) Charting the Growth of G.ST Antiviral in 2023 Send us Fan Mail Support the show Join the Podcast Newsletter: Link Your Next Move: Link

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Spark 20: Alex Dang | Everyone Agrees? Think Again. How Venture Capitalists Decide

    Nov 1, 202629 minAudio

    Invest in the wrong startup and you lose one times your money. Miss the next Google and you lose ten thousand times. Most boards are built to avoid the first mistake. Venture capitalists play by different rules. They...

    Credit the people on this episode

  2. EP 185: Ivy Nguyen | IQ, EQ and the Execution Quotient Investors Fund

    Oct 18, 20261 hr 4 minAudio

    The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small...

    Credit the people on this episode

  3. EP 184: Ivy Nguyen | 10,000 AI Pitches and the One Test That Matters

    Oct 15, 202659 minAudio

    In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown...

    Credit the people on this episode

  4. EP 183: Marie Schroeder | Send the Rough Deck, Not the Perfect One

    Sep 27, 20262 hr 5 minAudio

    A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it...

    Credit the people on this episode

  5. #182 - How to Lead When You Don't Know Where You Are Going: 4 Lessons from Ben Horowitz (Part 2 of 2)

    Sep 8, 202657 minAudio

    What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to...

    Credit the people on this episode